$81.38
2.26%
Nasdaq, Nov 19, 03:59 pm EST. Closed.
ISIN
US09075V1026
Symbol
BNTX

BioNTech SE - ADR Stock price

$81.38
-7.83 8.78% 1M
-6.41 7.30% 6M
-13.82 14.52% YTD
-20.05 19.77% 1Y
-17.45 17.66% 3Y
-204.54 71.54% 5Y
+67.33 479.13% 10Y
+67.33 479.13% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-1.88 2.26%
ISIN
US09075V1026
Symbol
BNTX
Industry

AI Insights on BioNTech SE - ADR Insights AI Insights on BioNTech SE - ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is BioNTech SE - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$20.6b
Enterprise Value
$5.0b
Net debt
positive
Cash
$16.1b
Shares outstanding
247.9m
Valuation
P/E
negative
P/S | estimate
7.8 | 10.0
EV/Sales | estimate
1.9 | 2.4
EV/FCF | ex SBC
negative | negative
P/B
1.1
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials
Revenue | estimate
$2.7b | $2.1b
EBITDA
$-539.3m
EBIT
$-1.5b
Net Income
$-1.6b
Free Cash Flow | ex SBC
$-521.8m | $-618.1m
Growth
Revenue | estimate
-23.2% | -34.7%
EBITDA
-305.6%
EBIT
-853.7%
Net Income
-157.7%
Free Cash Flow
56.6%
Margin
Gross
79.1%
EBITDA
-20.3%
EBIT
-56.9%
Net
-60.9%
Free Cash Flow | ex SBC
-19.7% | -23.3%
Financial Health
Equity Ratio
87.4%
Return on Equity
-5.9%
ROCE
-7.5%
ROIC
-37.4%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$96.3m | 3.6%
SBC as % of FCF
-
SBC Growth 1Y
-16.9%
Share Count Growth 1Y
3.1%
Shareholder Yield
-3.1%
More
EPS
$-6.4
FCF per Share
$-2.1
Short interest
3.5%
Employees
8k
Rev per Employee
$400.0k

BioNTech SE - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a BioNTech SE - ADR forecast:

20x Buy
69%
9x Hold
31%

Analyst Opinions

29 Analysts have issued a BioNTech SE - ADR forecast:

Buy
69%
Hold
31%

BioNTech SE - ADR Events

Past Events
NOV
3
Q3 2026 Earnings Call
17 days ago
AUG
4
Q2 2026 Earnings Call
4 months ago
MAY
5
Q1 2026 Earnings Call
7 months ago
MAR
10
Q4 2025 Earnings Call
9 months ago
JAN
13
44th Annual J.P. Morgan Healthcare Conference
10 months ago
NOV
11
Special Call - BioNTech SE
about one year ago
NOV
3
Q3 2025 Earnings Call
about one year ago

Financial data from BioNTech SE - ADR

Sep '26
+/-
%
2,655 2,655
23% 23%
100%
- Direct Costs 555 555
12% 12%
21%
2,100 2,100
29% 29%
79%
- Selling and Administrative Expenses 817 817
38% 38%
31%
- Research and Development Expense 2,404 2,404
1% 1%
91%
-539 -539
306% 306%
-20%
- Depreciation and Amortization 970 970
131% 131%
37%
EBIT (Operating Income) EBIT -1,510 -1,510
854% 854%
-57%
Net Profit -1,616 -1,616
158% 158%
-61%

In millions USD.

Don't miss a Thing! We will send you all news about BioNTech SE - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioNTech SE - ADR Stock News

Positive
Barrons
●
7 days ago
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
Neutral
GlobeNewsWire
●
17 days ago
Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead's TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breas...
More BioNTech SE - ADR News

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.

Head office Germany
CEO Prof. Sahin
Employees 7,807
Founded 2008
Website www.biontech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today